Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug;17(4):403-420.
doi: 10.1159/000524879. Epub 2022 May 5.

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022

Nina Ditsch  1 , Achim Wöcke  1   2 , Michael Untch  3 , Christian Jackisch  4 , Ute-Susann Albert  2 , Maggie Banys-Paluchowski  5 , Ingo Bauerfeind  6 , Jens-Uwe Blohmer  7 , Wilfried Budach  8 , Peter Dall  9 , Eva Maria Fallenberg  10 , Peter A Fasching  11 , Tanja N Fehm  12 , Michael Friedrich  13 , Bernd Gerber  14 , Oleg Gluz  15 , Nadia Harbeck  16 , Jörg Heil  17 , Jens Huober  18 , Hans H Kreipe  19 , David Krug  20 , Thorsten Kühn  21 , Sherko Kümmel  22 , Cornelia Kolberg-Liedtke  23 , Sibylle Loibl  24 , Diana Lüftner  25 , Michael Patrick Lux  26 , Nicolai Maass  27 , Christoph Mundhenke  28 , Ulrike Nitz  15 , Tjoung-Won Park-Simon  29 , Toralf Reimer  14 , Kerstin Rhiem  30 , Achim Rody  5 , Marcus Schmidt  31 , Andreas Schneeweiss  32 , Florian Schütz  33 , Hans-Peter Sinn  34 , Christine Solbach  35 , Erich-Franz Solomayer  36 , Elmar Stickeler  37 , Christoph Thomssen  38 , Isabell Witzel  39 , Volkmar Müller  39 , Wolfgang Janni  40 , Marc Thill  41
Affiliations
Review

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022

Nina Ditsch et al. Breast Care (Basel). 2022 Aug.

Abstract

Introduction: The AGO (Arbeitsgemeinschaft Gynäkologische Onkologie, German Gynecological Oncology Group) Task Force on Diagnosis and Treatment of Breast Cancer as an interdisciplinary team consists of specialists from gynecological oncology, pathology, diagnostic radiology, medical oncology, and radiation oncology with a special focus on breast cancer.

Methods: The updated evidence-based treatment recommendation 2022 for early breast cancer (EBC) and metastatic breast cancer of the AGO Task Force has been released.

Results and conclusion: This paper captures the update of EBC.

Keywords: Breast surgery; Communication; Early breast cancer; Postneoadjuvant therapy; Radiotherapy; Reconstruction.

PubMed Disclaimer

Conflict of interest statement

Prof. Dr. med. Nina Ditsch; Advisory Board: AstraZeneca, Daiichi-Sankyo, Lilly, Lukon, Molekular Health, MSD, Novartis, Gilead Sciences, onkowissen, Pfizer, Roche, Seagen; Lecture: Novartis, Pfizer, MSD. Prof. Dr. med. Achim Wöckel; Advisory board: Amgen, AstraZeneca, Aurikamed, Celgene, Eisai, Lilly, Novartis, Pfizer, Roche, Tesaro, Sirtex, MSD, Genomic Health, Pierre Fabre, Clovis, Organon. Prof. Dr. med. Christian Jackisch; Advisory board: Exact Sciences, Pfizer, Roche, GSK, Pierre-Fabre, Seagen; Lecture: AstraZeneca, Lilly, Novartis, Roche, Novartis, Amgen, Pierre-Fabre, Exact Sciences, MSD. Prof. Dr. med. Michael Untch; Advisory board: Lilly, AstraZeneca, Pfizer, Roche, Pierre Fabre, Sanofi Aventis, Gilead Science; Lecture: Daiichi Sankyo, Lilly, Seagen, Novartis, AstraZeneca, Roche, Eisai, MSD, I-Med_Insitute, Onkowissen, art tempi, High5Med. Prof. Dr. med. Ute-Susann Albert; Lectures and/or consulting: Pfizer, Novartis, Aurikamed. PD Dr. Malgorzata Banys-Paluchowski; Advisory board: Novartis, Roche, LIlly, Pfizer, GSK, MSD. Lecture: Novartis, Pfizer, pfm medical, Seagen, Daiichi Sankyo, Lilly, Roche, Amgen; Trial funding: Mammotome, Exact Sciences, Merit Medical, Endomag. Dr. med. Ingo Bauerfeind; No conflicts of interest. Prof. Dr. med. Jens-Uwe Blohmer; Honoraria: Astrazeneca, Eisai, Lilly, MSD, Novartis, Pfizer, Roche, Seagen. Prof. Dr. med. Wilfried Budach; Lecture: Merck, medpublico GmbH, BVDST. Prof. Dr. med. Peter Dall; Advisory Boards: Gilead Science, Roche; Lecture: Novartis, AstraZeneca, Pfizer. PD Dr. med. Eva Maria Fallenberg; No conflicts of interest. Prof. Dr. med. Peter A. Fasching; Advisory board: Pfizer, Novartis, Roche, Daiichi Sankyo, Eisai, AstraZeneca, Lilly, MSD, Seagen, Agendia, Pierre Fabre, Sanofi Aventis, Gilead Science; Lecture: Pfizer, Novartis, Roche, Daiichi Sankyo, Eisai, AstraZeneca, Lilly, MSD, Seagen, Gilead Sciences; Other: Onkowissen, art tempi. Prof. Dr. med. Tanja N. Fehm; Onkowissen. Prof. Dr. med. Michael Friedrich; Advisory Board: Gilead Sciences; Other honoraria: Roche, MSD; Stockholding: Biontech, Curevac. Prof. Dr. med. Bernd Gerber; Lecture honoraria: Roche, AstraZeneca, Seagen, Novartis, Pfizer, MedConcept; Others: Pfizer. PD Dr. med. Oleg Gluz; No conflicts of interest. Prof. Dr. med. Nadia Harbeck; Honoraria for lectures and/or consulting: Amgen, AstraZeneca, Daiichi Sanyko, Gilead Science, Lilly, MSD, Novartis, Pierre-Fabre, Pfizer, Roche, Sandoz, Seagen, Exact Sciences; Minority share holder: Westdeutsche Studiengruppe (WSG). Prof. Dr. med. Jörg Heil; Advisory board: Polytech; Trial funding: pfm medical. Prof. Dr. med. Jens Huober; Lecture: Giled Science, Seagen, Lilly, Novartis, Daiichi Sankyo, GSK, Pfizer. Prof. Dr. med. Hans-Heinrich Kreipe; Advisory board: Lilly; Lecture: AstraZeneca, Roche, Daiichi Sankyo, Pfizer. Dr. David Krug; Lecture: MSD, ESO, ESMO, medupdate GmbH; Trial funding: Merck. Prof. Dr. med. Thorsten Kühn, Advisory Board: Sysmex, Neodynamics; Trial funding: Merit Medical, Endomag, Mammotome; Lecture: Pfizer. Prof. Dr. med. Sherko Kümmel; Lecture: Roche, Lilly, Exact Sciences, Novartis, Amgen, Daiichi Sankyo, AstraZeneca, Somatex, MSD, Pfizer, pfm medical, Seagen, Gilead Science, Agendia; Other honoraria: Roche, Daiichi Sankyo, Sonoscape; Advisory board: Lilly, MSD, Roche. Prof. Dr. med. Cornelia Kolberg-Liedtke; Advisory board: Aurikamed, Novartis, Pfizer, MSD, Novartis, Gilead Science, Seagen, Lilly, Agendia, Daiichi Sankyo; Lecture: Roche, Novartis, Pfizer, Exact Sciences, Amgen, AstraZeneca, Carl Zeiss Meditec, NCO Hannover; Other: Gilead Science, POMME; Stockholding: Phaon Scientific; Trial Funding: Gilead Science. Prof. Dr. med. Sibylle Loibl; Trial funding: Abbvie, AstraZeneca, Celgene, Daiichi Sankyo, Gilead Science, Novartis, Pfizer, Roche; Lecture: Abbvie, Amgen, AstraZeneca, Bayer, BMS, Celgene, Daiichi Sankyo, Eirgenix, GSK, Gilead Science, Lilly, Merck, Novartis, Pfizer, Pierre Fabre, Prime/Medscape, Puma, Roche, Samsung. Prof. Dr. med. Michael Patrick Lux; Lecture: Lilly, Roche, MSD, Onkowissen, Novartis, Pfizer, Exact Sciences, Daiichi Sankyo, Gilead, Grünenthal, Eisai, AstraZeneca; Advisory board: pfm medical, Saman Tree, Sysmex, Lilly, AstraZeneca, MSD, Novartis, Pfizer, Eisai, Gilead, Exact Sciences, Daiichi Sankyo, Grünenthal, Pierre fabre, PharmaMar, Roche; Other: Medac, Pfizer. Prof. Dr. med. Nicolai Maass; Advisory board: Amgen, Grünenthal. Lecture: AstraZeneca, Pierre Fabre, Clovis, Seagen, Lilly, MSD, Novartis, Pfizer. Prof. Dr. med. Christoph Mundhenke; Not specified. Prof. Dr. med. Ulrike Nitz; Not specified. Prof. Dr. Tjoung-Won Park-Simon; Advisory board: Roche, AstraZeneca, GSK, Pfizer, Lilly, MSD, Exact Sciences, Daiichi Sankyo, Seagen, Novartis, Gilead Science; Lecture: Roche, AstraZeneca, GSK, Pfizer, Lilly, MSD, NCO, Exact Sciences, Daiichi Sankyo, Seagen, Novartis, Gilead Science. Prof. Dr. med. Toralf Reimer; Trial funding: Novartis, German Cancer Aid and Else Kroener-Fresenius-Stiftung; Advisory board: MSD, Novartis, Myriad; Lecture: Pfizer, Novartis, Roche, AstraZeneca. PD. Dr. med. Kerstin Rhiem; Lecture: AstraZeneca, Amgen, MDS, Medupdate, Medconcept. Prof. Dr. med. Achim Rody; Advisory board: AstraZeneca, Novartis, Roche, Exact Sciences, Pierre Fabre, Lilly, Seagen, Amgen, MSD; Lecture: Pfizer, Celgene, Eisai; Trial funding: Eisai. Prof. Dr. med. Marcus Schmidt; Advisory board: AstraZeneca, Novartis, Eisai, Lilly, MSD, Pierre Fabre, Pfizer, Roche, Seagen. Prof. Dr. med. Andreas Schneeweiss; Lecture: Amgen, AstraZeneca, Aurikamed, Clinsol, ConnectMedica, Gilead Science, GSK, I-Med, Lilly, MSD, Nanostring, Novartis, Onkowissen, Promedicis, Pfizer, Pierre Fabre, Roche, Seagen, StreamedUp; Other: Thieme. Prof. Dr. med. Florian Schütz; Lecture: Amgen, AstraZeneca, Eisai, Pfizer, Novartis, Onkowissen; Advisory board: Amgen, Lilly, MSD, Eisai. Prof. Dr. med. Hans-Peter Sinn; Advisory board: Diaceutics. Prof. Dr. med. Christine Solbach; Lecture: DiaLog Service GmbH, Jörg Eickeler, Pfizer, MedConcept, Medicultus, GBG, Dt. Röntgengesellschaft, BVF Akademie, LÄK Hessen Akademie, Meet the Expert Academy; Advisory board: MSD, Roche. Prof. Dr. med. Erich-Franz Solomayer; Lecture: Universitätsklinikum Freiburg, MedConcept, Saarländische Krebsgesellschaft, Bsh medical Communications GmbH, Pfizer, AstraZeneca; Other: Roche, Amgen, Clovis, AstraZeneca, Novartis, GSK, MSD, Eisai, Pfizer, Medac, Pierre Fabre, PharmaMar, Daiichi Sankyo, Samsung, Primus, matramed, GE Healthcare; Trial funding: Medac, GBG, AMS, AstraZeneca, Pfizer, Novartis, AGO Research GmbH, WSG, Universitätsklinikum Tübingen, Roche. Prof. Dr. med. Elmar Stickeler; Advisory boards: Gilead, Iomedico, Lilly, MSD, Seagen; Lecture: Pfizer, Bsh Düsseldorf, Gilead, Iomedico, PharmaMar, Onkowissen, Roche. Prof. Dr. med. Christoph Thomssen; Advisory board: Amgen, AstraZeneca, Hexal, Lilly, MSD, Pfizer, Roche, Seagen; Lecture: Klnikum Wolfsburg, Medicultus, Medupdate, Novartis, Pfizer, Roche, AstraZeneca, Daiichi Sankyo, Jörg Eickeler, Evang. KH Wittenberg, Gilead Science: Other: Aurikamed, ForumSanitas/Merit Corporate, Onkowissen, Pfizer, Daiichi Sankyo. Prof. Dr. Isabell Witzel; Lecture: Daiichi Sankyo, Pfizer, MSD, Lilly, Seagen, AstraZeneca; Other: Onkowissen; Prof. Dr. med. Volkmar Müller; Lecture: Amgen, AstraZeneca, Daiichi Sankyo, eisai, GSK, Pfizer, MSD, Medac, Novartis, Roche, Teva, Seagen, Onkowissen, High5Oncology, Medscape, Gilead; Advisory board: Hexal, Roche, Pierre Fabre, Amgen, Clinsol, Novartis, MSD, Daiichi Sankyo, Eisai, Lilly, Sanofi Aventis, Seagen, Gilead Science; Trial funding: Novartis, Roche, Seagen, Genetech; Other: Daiichi Sankyo. Prof. Dr. med. Wolfgang Janni; Lecture: Amgen, AstraZeneca, Daiichi Sankyo, Lilly, MSD, Novartis, Pfizer, Roche, Seagen, Gilead Science; Trial Funding: Amgen, AstraZeneca, Lilly, Novartis, Roche. Prof. Dr. med. Marc Thill; Advisory boards: Agendia, Amgen, AstraZeneca, Aurikamed, Becton and Dickinson, ClearCut, Clovis, Daiichi Sankyo, Eisai, Exact Sciences, Gilead Science, Grünenthal, GSK, Lilly, MSD, Neodynamics, Novartis, Onkowissen, Organon, Pfizer, pfm Medical, Pierre-Fabre, Roche, Seagen, Sirius Pintuition, Sysmex; Manuscript support: Amgen, Clearcut, Clovis, pfm medical, Roche, Servier; Travel reimbursement: Amgen, art tempi, AstraZeneca, Clovis, Connect Medica, Daiichi Sankyo, Eisai, Exact Sciences, Lilly, MSD, Novartis, Pfizer, pfm Medical, Roche, Seagen; Congress support: Amgen, AstraZeneca, Daiichi Sanyko, Novartis, Pfizer, Roche; Lecture: Amgen, art tempi, AstraZeneca, Clovis, Connect Medica, Daiichi Sankyo, Exact Sciences, Gilead Science, Hexal, I-Med-Institute, Jörg Eickeler, Lilly, MSD, Novartis, Onkowissen, Pfizer, pfm medical, Roche, Seagen, Sysmex, Vifor, Viatris, Trial funding: Endomagnetics, Exact Sciences. We have no acknowledgements for this article.

Figures

Fig. 1
Fig. 1
a–dRare and salivary-type TNBC: tumors with divergent clinical behavior and specific genetic alterations.
See this image and copyright information in PMC

References

    1. Empfehlungen Gynäkologische Onkologie kommission mamma. 2021. Available from www.ago-online.
    1. www.cebm.net .
    1. Lovrics O, Butt J, Lee Y, Lovrics P, Boudreau V, Anvari M, et al. The effect of bariatric surgery on breast cancer incidence and characteristics: a meta-analysis and systematic review. Am J Surg. 2021;222((4)):715–22. - PubMed
    1. He Y, Tao Q, Zhou F, Si Y, Fu R, Xu B, et al. The relationship between dairy products intake and breast cancer incidence: a Meta-Analysis of Observational Studies. BMC Cancer. 2021;21((1)):1109. - PMC - PubMed
    1. Poorolajal J, Heidarimoghis F, Karami M, Cheraghi Z, Gohari-Ensaf F, Shahbazi F, et al. Factors for the primary prevention of breast cancer: a Meta-Analysis of Prospective Cohort Studies. J Res Health Sci. 2021;21((3)):e00520. - PMC - PubMed